The latest update is out from Scholar Rock Holding (SRRK).
Scholar Rock Holding Corporation revealed promising results from its Phase 1 DRAGON trial of SRK-181 with pembrolizumab for advanced solid tumors at the ASCO 2024 Annual Meeting, showing the treatment’s good tolerance and encouraging responses in various cancers. Key findings included a correlation between CD8+ T-cell presence and improved response rates in renal cell carcinoma. The company plans to discuss the details in a conference call and suggests that CD8+ status and regulatory T-cell levels may be biomarkers for identifying patients most likely to benefit from the treatment.
Learn more about SRRK stock on TipRanks’ Stock Analysis page.
